CLINICAL TRIALS
Why participate in a clinical trial? We can’t advance science to help cure Alzheimer’s without participating in trials that test the efficacy and safety of drugs and clinical protocols. Use this page as a resource to find the right trial for you. We’re including a link to register for trials that might be taking place near you.
Ongoing Trials That Need Your Help:
The TRAILBLAZER-ALZ 2 Clinical Research Study is evaluating the safety and effectiveness of an investigational drug for people with early symptomatic Alzheimer’s disease.
The study involves people who have memory loss that has gotten worse over the last last six months or more. If you are experiencing memory loss or struggling to perform complex tasks, you may pre-qualify.
Participants are randomly assigned into one of two groups. They receive either the investigational drug or a placebo.
If you qualify, participation can last up to 2.5 years, with up to 26 appointments with the study center.
Click HERE to learn more.
Who can participate?
This study is seeking 1,000 volunteers of all races, ethnicities, and backgrounds who are:
- 60 to 85 years old
- With or without memory loss
- Have someone who can participate with you as a study partner
What does the study involve?
This study requires two (2) visits with the research study staff and one (1) visit to a local imaging site over approximately three (3) months. A follow-up phone call will occur depending on your brain amyloid PET scan results. No experimental treatments are part of this study.
Click HERE to learn more.
Can Lifestyle Changes Reverse Alzheimer’s Disease?
Dr. Dean Ornish and his colleagues are conducting the first randomized controlled trial to determine if the progression of early stage Alzheimer’s disease may be slowed, stopped, or perhaps even reversed by a comprehensive lifestyle medicine program, without drugs, devices, or surgery.
This lifestyle medicine program includes a whole foods low-fat, low-sugar plant-based diet; moderate exercise; stress management techniques including meditation; and psychosocial support.
Click HERE to learn more and enroll in the trial.
University of San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI)
The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a grant expected to total $5 million over five years to the University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.
Gene therapy is an experimental technique that uses genes or gene products to treat or prevent disease instead of relying on drugs or surgery.
The clinical trial, developed by principal investigator Mark Tuszynski, MD, PhD, professor of neuroscience and director of the Translational Neuroscience Institute at UC San Diego School of Medicine, delivers the brain-derived neurotrophic factor (BDNF) gene into the brains of qualifying trial participants where it is hoped it will prompt production of BDNF in nearby cells.
The three-year-long trial will recruit 12 participants with either diagnosed AD or MCI to receive AAV2-BDNF treatment, with another 12 persons serving as comparative controls over that period.
The clinical trial has begun enrolling participants, but multiple slots remain available. For more information on the trial, contact Michelle Mendoza at 858-534-8857 or email genetherapy@ucsd.edu.
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)
Cleveland Clinic Lou Ruvo Center for Brain Health – Las Vegas
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial).
Click HERE to learn more.
Resources to Clinical Trials Suited to You: